Healthcare • Biotechnology
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if ACET is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
19 top institutions tracked
Last 13F trend: distributing (light)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 1
56 filers reported a long position in ACET for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $8.1M | 932.6K | -21.1% |
| ORBIMED ADVISORS LLC | $7.3M | 844.8K | -17.8% |
| FRANKLIN RESOURCES INC | $5.4M | 626.6K | Unchanged |
| CITADEL ADVISORS LLC | $3.7M | 432.7K | +13.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | $3M | 343.2K | +2% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $2.4M | 274.4K | Unchanged |
| RENAISSANCE TECHNOLOGIES LLC | $2.3M | 265.9K | +14.3% |
| Stonepine Capital Management, LLC | $2.1M | 245.5K | +10.6% |
| Alyeska Investment Group, L.P. | $1.8M | 203.8K | Unchanged |
| Schonfeld Strategic Advisors LLC | $1.7M | 195.5K | New |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.